Medtronic has reported positive preliminary results from the HVAD LATERAL clinical trial of a full-support ventricular assist device (VAD) 'HVAD system' to treat patients with advanced heart failure.

HVAD system is a mechanical pump designed to circulate blood in the body through a less invasive procedure called thoracotomy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results indicated that the trial has met its primary endpoint at six months, with 87.6% of subjects being alive and free of disabling strokes, having received a heart transplant, or transferred due to recovery.

The prospective LATERAL trial evaluated the thoracotomy implant technique that is performed by making a small, lateral, surgical incision on the left side of the chest, in between the ribs.

"This innovative technique was pioneered by clinicians whose contributions have helped to significantly advance the field of mechanical circulatory support."

At 30 centres in the US and Canada, the trial recruited 145 patients who have not responded to conventional medical management and are eligible for heart transplantation.

Medtronic Heart Failure business vice-president and general manager David Steinhaus said: "The LATERAL trial represents positive, contemporary results with the HVAD System, with overall survival rates of nearly 92% at six months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This innovative technique was pioneered by clinicians whose contributions have helped to significantly advance the field of mechanical circulatory support. The data presented today support this less-invasive surgical approach."

It is reported that the implant of the left VAD device through the thoracotomy technique preserves the chest for a subsequent sternotomy.

The adverse events found at 30 days of the trial include cardiac arrhythmia, right heart failure, bleeding requiring reoperation and stroke.